Skip to main content

Table 2 Characteristics of patients in the training set

From: Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis

Sample ID

Age (years)

Sex

Bacterial isolation

Antibiotherapy before blood collection

Underlying diseases

Survival

Other sepsis (n = 13)

      

   I001*

52

Male

Streptococcus non-group A or B

Ceftriaxone

-

Non-survivor

   I002†‡

52

Female

A. baumannii

Ceftazidime, bactrim

T2D, CRF, lung edema

Survivor

   I004* ‡

45

Male

Salmonella serotype B

Cloxacillin, ceftriaxone

T2D, arthritis

Survivor

   I006* §

37

Male

C. albicans

Ceftriaxone, sulperazone, bactrim

HIV infection, tuberculosis

Survivor

   I007*

73

Female

Corynebacterium spp.

-

NSAID-induced GI bleeding

Non-survivor

   I008†¶

70

Female

E. coli

Bactrim, ceftazidime

T2D

Survivor

   I009*

52

Female

S. aureus

Ceftazidime, cloxacillin

T2D, knee abscess

Survivor

   I010†‡¥

72

Female

E. coli

Ceftriaxone

T2D, CRF

Survivor

   I011* ¶

38

Female

E. coli

-

HCV infection

Survivor

   I012* §

69

Female

C. albicans

Ceftazidime

RF

Survivor

   I013*

74

Female

Corynebacterium spp.

Ceftazidime, clarithromycin

Chronic heart failure, COPD

Survivor

   I014*

54

Female

Salmonella spp.

Ceftriaxone, ceftazidime, levofloxacin

T2D, endometrial cancer, ITP

Survivor

   I015* §

41

Male

C. albicans

Ceftazidime

HIV infection

Survivor

Septicemic melioidosis (n = 11)

      

   M001*

68

Male

B. pseudomallei

Ceftazidime, bactrim

Chronic heart failure, COPD

Non-survivor

   M002*

43

Female

B. pseudomallei

Ceftriaxone, ceftazidime

T2D

Survivor

   M003*

55

Male

B. pseudomallei

Ceftazidime

-

Non-survivor

   M006*

46

Male

B. pseudomallei

Ceftriaxone

T2D, chirrosis

Non-survivor

   M007*

50

Male

B. pseudomallei

Ceftazidime, tazocin

Lung cancer

Survivor

   M008*

70

Female

B. pseudomallei

Ceftazidime, bactrim

T2D

Non-survivor

   M009*

48

Female

B. pseudomallei

Sulperazone

T2D

Survivor

   M010*

48

Male

B. pseudomallei

Ceftriaxone, ceftazidime, doxycycline

T2D

Survivor

   M012*

56

Male

B. pseudomallei

Sulperazone, bactrim, cetazidime

T1D, ARF

Survivor

   M014*

65

Female

B. pseudomallei

Cloxacilin, ceftazidime

T2D, chirrosis

Non-survivor

   M015*

41

Male

B. pseudomallei

Bactrim, ceftazidime

-

Survivor

  1. *Community-acquired septicemia; †hospital-acquired septicemia;‡mechanical ventilation;§taken immunosuppressive;¶urinary catheterized drugs; ¥blood transfused. ARF, acute renal failure; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; GI, gastrointestinal tract; NSAID, non-steroidal anti-inflammatory drug; RF, renal failure; T2D, type 2 diabetes; TP, idiopathic thrombocytopenic purpura.
Back to article page

Genome Biology

ISSN: 1474-760X

Contact us